Endologix Announces Equity Financing of $52 Million and Debt Restructuring Addressing 2020 Maturities and Financial Covenants – Global Banking And Finance Review
Endologix, Inc. (Nasdaq: ELGX) (the Company), a developer and marketer of innovative treatments for aortic disorders, today announced that it has entered into a definitive agreement to raise approximately $52 million gross cash proceeds through the issuance of approximately 7.9 million new shares of the Companys common stock at a purchase price of $6.61 per…